Overview

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Status:
Unknown status
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
Determination of response rate Assessment of toxicity and determination of "time to progression"
Phase:
Phase 2
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborator:
ribosepharm GmbH
Treatments:
Bendamustine Hydrochloride